Encouraged by the efficacy of PAR-Lipo/pEGFP + O2@PL in delivering O2 and boosting P53 expression in vitro, we aimed to evaluate their antitumor efficacy in MCF-7-induced breast cancer models. This evidence concerns the gene TP53 and breast carcinoma.